Drug: Alphanate

Antihemophilic Factor (Human), Alphanate (antihemophilic factor) ®, Solvent Detergent / Heat Treated, is a single dose, sterile, lyophilized concentrate of Factor VIII (AHF) intended for intravenous administration in the treatment of hemophilia A, or acquired Factor VIII deficiency. Alphanate (antihemophilic factor) ® is prepared from pooled human plasma by cryoprecipitation of the Factor VIII, fractional solubilization, and further purification employing heparin-coupled, cross-linked agarose which has an affinity to the heparin binding domain of vWf/FVIII:C complex.1 The product is treated with a mixture of tri(n-butyl) phosphate (TNBP) and polysorbate 80 to reduce the risks of transmission of viral infection. In order to provide an additional safeguard against potential non-lipid enveloped viral contaminants, the product is also subjected to a 80 °C heat treatment step for 72 hours. However, no procedure has been shown to be totally effective in removing viral infectivity from coagulation factor products. Alphanate® is labeled with the antihemophilic factor potency (Factor VIIIC activity) expressed in International Units (I U) per vial, which is referenced to the WHO International Standard. Alphanate (antihemophilic factor) ® contains Albumin (Human) as a stabilizer, resulting in a final container concentrate with a specific activity of at least 5 IU FVIII:C/mg total protein. Prior to the addition of the Albumin (Human) stabilizer, the specific activity is significantly higher. When reconstituted with the appropriate volume of Sterile Water for Injection, USP, Alphanate (antihemophilic factor) ® contains 0.3 - 0.9 g Albumin (Human)/100 mL; NMT 5 mmol calcium/L; NMT 750 µg glycine/IU FVIIIC; NMT 1.0 U heparin/mL; 10 - 40 mmol histidine/L; NMT 0.1 mg imidazole/mL; 50 - 200 mmol arginine/L; NMT 1.0 µg polyethylene glycol and polysorbate 80/IU FVIII:C; NMT 10 mEq sodium/vial; and NMT 0.1 µg TNBP/IU FVIIIC.

Source: http://www.rxlist.com

Adverse reactions may include urticaria, fever, chills, nausea, vomiting, headache, somnolence, or lethargy. Occasionally, mild reactions occur following the administration of Antihemophilic Factor (Human)13, such as allergic reactions, chills, nausea, or stinging at the infusion site. If a reaction is experienced, and the patient requires additional Antihemophilic Factor (Human), product from a different lot should be administered. Massive doses of Antihemophilic Factor (Human) have rarely resulted in acute hemolytic anemia, increased bleeding tendency or hyperfibrinogenemia.14 Alphanate (antihemophilic factor) ® contains blood group specific isoagglutinins and, when large and/or frequent doses are required in patients of blood groups A, B, or AB, the patient should be monitored for signs of intravascular hemolysis and falling hematocrit. Should this condition occur, thus leading to progressive emolytic anemia, the administration of serologically compatible type O red blood cells should be considered or the administration of Antihemophilic Factor (Human) produced from group-specific plasma should be considered. Read the Alphanate (antihemophilic factor) Side Effects Center for a complete guide to possible side effectsLearn More »

Source: http://www.rxlist.com

For adult usage Following reconstitution with the supplied diluent, Alphanate (antihemophilic factor) ® should be administered intravenously within three hours after reconstitution to avoid the potential ill effect of any inadvertent bacterial contamination occurring during reconstitution. Alphanate (antihemophilic factor) ® may be administered by injection (plastic disposable syringes are recommended). Administer at room temperature, do not refrigerate after reconstitution, and discard any unused contents into the appropriate safety container. Antihemophilic factor potency (Factor VIII:C activity) is expressed in International Units (IU) on the product label. One unit approximates the activity in one mL of normal human plasma. Replacement therapy studies have shown a linear dose-response relationship with a 2.0-2.5% increase in Factor VIII activity for each unit of Factor VIII:C per kg of body weight transfused, from which an approximate factor of 0.5 lU/kg can be calculated.15,16 The following formula provides a guide for dosage calculation (the plasma Factor VIII may vary depending upon the age, weight, severity of hemorrhage, or surgical procedure of the patient): Bodyweight (in kg) X 0.50 lU/kg X Factor VIII Increase Desired (Percent) = Number of Factor VIII:C IU Required Example: 50 kg X 0.50 lU/kg X 30 (% increase) = 750 IU Factor VIII:C Mild to moderate hemorrhages can usually be treated with a single administration of Alphanate (antihemophilic factor) ® sufficient to raise the plasma Factor VIII level to 20 to 30%. In the event of more serious hemorrhage, the patient's plasma Factor VIII level should be raised to 30 to 50%. Infusions are generally required at twice daily intervals over several days.16 Surgery in patients with Factor VIII deficiency requires that postoperatively the Factor VIII level be raised to 50 to 80% and maintained at or above 30% for approximately two weeks. For dental extractions, the Factor VIII level should be raised to 50% immediately prior to the procedure; additional Alphanate (antihemophilic factor) ® may be given if bleeding recurs.17 In patients with severe Factor VIII deficiency who experience frequent hemorrhages, Antihemophilic Factor (Human), Alphanate (antihemophilic factor) ®, may be administered prophy-lactically on a daily or every other day schedule to raise the Factor VIII level to approximately 15%.18 Factor VIII levels should be monitored periodically to evaluate individual patient response to the dosage regime. For pediatric usage See PRECAUTIONS RECONSTITUTION Always Use Aseptic Technique
  1. Warm diluent (Sterile Water for Injection, USP) and concentrate (Alphanate (antihemophilic factor) ®) to at least room temperature (but not above 37 °C).
  2. Remove plastic caps from the diluent and concentrate vials.
  3. Swab the exposed stopper surfaces with a cleansing agent such as alcohol. Do not leave excess cleansing agent on the stoppers.
  4. Remove cover from one end of the double-ended transfer needle. Insert the exposed end of the needle through the center of the stopper in the DILUENT vial.
  5. Remove plastic cap from the other end of the double-ended transfer needle now seated in the stopper of the diluent vial. To reduce any foaming, invert the vial of diluent and insert the exposed end of the needle through the center of the stopper in the CONCENTRATE vial at an angle, making certain that the diluent vial is always above the concentrate vial. The angle of insertion directs the flow of diluent against the side of the concentrate vial. Refer to Figure 1. There should be enough vacuum in the vial to transfer all of the diluent.

  6. Figure 1
  7. Disconnect the two vials by removing the transfer needle from the diluent vial stopper. Remove the double-ended transfer needle from the concentrate vial and discard the needle into the appropriate safety container.
  8. Let the vial stand until contents are in solution, then GENTLY swirl until all concentrate is dissolved. Reconstitution requires less than 5 minutes.
  9. DO NOT SHAKE THE CONTENTS OF THE VIAL. DO NOT INVERT THE CONCENTRATE VIAL UNTIL READY TO WITHDRAW CONTENTS.
  10. Use as soon as possible after reconstitution.
  11. After reconstitution, parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. When reconstitution procedure is strictly followed, a few small particles may occasionally remain. The microaggregate filter will remove particles and the labeled potency will not be reduced.
ADMINISTRATION BY SYRINGE Use Aseptic Technique
  1. Peel cover from microaggregate filter package and securely install the syringe into the exposed Luer inlet of the filter, using a slight clockwise twisting motion.
  2. Remove filter from packaging. Remove protective cover from the spike end of the filter.
  3. Pull back plunger drawing sufficient air into the syringe to allow reconstituted product to be withdrawn as described in the next step.
  4. Insert the spike end of the filter into the reconstituted concentrate vial. Inject air (Figure 2a) and withdraw the reconstituted product from the vial into the syringe (Figure 2b).

  5. Figure 2a               Figure 2b
  6. Remove the filter from the syringe; discard the filter and the empty concentrate vial, into the appropriate safety container. Attach syringe to an infusion set, expel air from the syringe and infusion set. Perform venipuncture and administer slowly at a rate not exceeding 10 mL/minute.
  7. If the patient is to receive more than one vial of concentrate, the infusion set will allow administration of multiple vials to be performed with a single venipuncture.
  8. Discard all administration equipment after use into the appropriate safety container. Do not reuse.

Source: http://www.rxlist.com

No information provided. REFERENCES 13. Rizza, C.R., Biggs, R. Blood Products in the Management of Haemophilia and Christmas Disease. In: Poller, L, ed. Recent Advances in Blood Coagulation, Boston: Little Brown, 1969, pp.1 79-1 95. 14. Hathaway, W.E., Mahasandana, C, Clarke, S. Alteration of Platelet Function After Transfusion in Hemophilia. Proc 14th Ann Mtg, Am Soc Hematol 1971, Abstracts, 58, No. 88. Last reviewed on RxList: 11/14/2008
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Antihemophilic Factor (Human), Alphanate (antihemophilic factor) ®, is indicated for the prevention and control of bleeding in patients with Factor VIII deficiency due to hemophilia A or acquired Factor VIII deficiency.7 No clinical trials have as yet been conducted using Alphanate (antihemophilic factor) ® for treatment of von Willebrand's disease, therefore the product is not approved for this use.

Source: http://www.rxlist.com

None known. Last reviewed on RxList: 11/14/2008
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

No information provided.

Source: http://www.rxlist.com

Alphanate (antihemophilic factor) ® is supplied in sterile, lyophilized form in single dose vials accompanied by a suitable volume of diluent (Sterile Water for Injection, USP), according to AHF potency. Each vial is labeled with the Factor VIIIC potency expressed in AHF International Units. Alphanate (antihemophilic factor) ® is packaged with a double-ended transfer needle and microaggregate filter for use in administration. Storage Alphanate (antihemophilic factor) ® should be stored at temperatures between 2 and 8 °C. Do not freeze to prevent damage to diluent vial. May be stored at room temperature not to exceed 30 °C for up to 2 months. When removed from refrigeration, record the date removed on the space provided on the carton. REFERENCES 7. Eyster, M.E. Hemophilia: A Guide for the Primary Care Physician. Postgraduate Medicine 1978, 64:75-81. 15. Shanbrom, E., Thelin, M. Experimental Prophylaxis of Severe Hemophilia with a Factor VIII Concentrate. JAM A 1969, 208(9): 1 853-1 856. 16. Levine, P.H. Hemophilia and Allied Conditions. In: Current Therapy in Hematology-On-cology: 1983-1984. Brain, M.C. (ed) New York: BC Decker, 1983, pp. 147-152. 17. Kasper, C.K. Hemophilia and Hemophilioid Disorders. In: Conn, H.F., ed. Current Therapy, 4th ed., Philadelphia: Saunders, 1974, pp. 258-263. 18. Kasper, C.K., Dietrich, S.L., Rapaport, S.I. Hemophilia Prophylaxis with Factor VIII Concentrate. Arch Intern Med 1970, 125:1004-1009. Manufactured by: Grifols Biologicals Inc., Los Angeles, CA 90032, USA. Revised January 2004. FDA rev date: n/a Last reviewed on RxList: 11/14/2008
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

General Antihemophilic Factor (Human), Alphanate (antihemophilic factor) ®, should not be administered at a rate exceeding 10 mL/minute. Rapid administration of a Factor VIII concentrate may result in vasomotor reactions. Some patients develop inhibitors to Factor VIII. Factor VIII inhibitors are circulating antibodies (i.e., globulins) that neutralize the procoagulant activity of Factor VIII. No studies have been conducted with Alphanate (antihemophilic factor) ® to evaluate inhibitor formation. Therefore, it is not known whether there are greater, lesser or the same risks of developing inhibitors due to the use of this product than there are with other antihemophilic factor preparations. Patients with these inhibitors may not respond to treatment with Antihemophilic Factor (Human), or the response may be much less than would otherwise be expected; therefore, larger doses of Antihemophilic Factor (Human) are often required. The management of bleeding in patients with inhibitors requires careful monitoring, especially if surgical procedures are indicated.10-12 Nursing personnel, and others who administer this material, should exercise appropriate caution when handling due to the risk of exposure to viral infection. Discard any unused contents into the appropriate safety container. Discard administration equipment after single use into the appropriate safety container. Do not resterilize components. Pregnancy Category C Animal reproduction studies have not been conducted with Alphanate (antihemophilic factor) ®. Therefore, it is not known whether it can cause fetal harm when administered to a pregnant woman or affect the reproductive capacity of a woman. Alphanate (antihemophilic factor) ® should be given to a pregnant woman only if clearly needed. Pediatric Use Clinical trials for safety and effectiveness in pediatric patients 16 years of age and younger have not been conducted. Across well controlled half-life and recovery clinical trial in patients previously treated with Factor VIII concentrates for Hemophilia A, the one pediatric patient receiving Alphanate (antihemophilic factor) ® (solvent detergent) responded similarly when compared with 12 adult patients.4 No adverse events were reported in either pediatric or adult patients with Alphanate (antihemophilic factor) ®.4 REFERENCES 4. Data on file at Grifols Biologicals Inc. 8. Biggs, R. Jaundice and Antibodies Directed Against Factors VIII and IX in Patients Treated for Haemophilia or Christmas Disease in the United Kingdom. Br J Haematol 1974, 26:313-329. 9. Kasper, C.K., Kipnis, S.A. Hepatitis and Clotting Factor Concentrates. JAMA 1972,221:510. 10. Kasper, C.K. Incidence and Course of Inhibitors Among Patients with Classic Hemophilia. Thromb Diath Haemorrh (Stuttg) 1973, 30:263-271. 11. Rizza, C.R., Biggs, R. The Treatment of Patients Who Have Factor VIII Antibodies. Br ] Haematol 1973, 24:65-82. 12. Roberts, H.R., Knowles, M.R., Jones, T.L., McMillan, C. The Use of Factor VIII in the Management of Patients with Factor VIII Inhibitors. In: Brinkhous, K.M., ed. Hemophilia and New Hemorrhagic States, International Symposium, New York, University of North Carolina Press, 1970, pp.152-163. Last reviewed on RxList: 11/14/2008
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Health Services in Toronto

Drug Database Online

Welcome to WebHealthNetwork an online drug guide and dictionary, here you can get drug information and definitaions for most popular pharmaceutical and medicinal drugs, and specifically Alphanate. Find what medications you are taking today.